Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC5R | P33032 | 11/20 | 0.42 |
| ▸ | MC3R | P41968 | 11/20 | 0.42 |
| ▸ | MC4R | P32245 | 10/20 | 0.42 |
| ▸ | MC1R | Q01726 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085154 | 0.83 | ACHE (0.33) | ACHE | |
| SCHEMBL12387465 | 0.82 | MC5R (0.46) | MC5RMC3RMC4RMC1RACHE | |
| SCHEMBL12387574 | 0.82 | MC5R (0.46) | MC5RMC3RMC4RMC1RACHE | |
| SCHEMBL10085176 | 0.82 | MC5R (0.46) | MC5RMC3RMC4RMC1RACHE | |
| SCHEMBL13045389 | 0.81 | MC5R (0.46) | MC5RMC3RMC4RMC1RACHE | |
| SCHEMBL12387502 | 0.77 | MC5R (0.43) | MC5RMC3RMC4R | |
| SCHEMBL12387504 | 0.75 | MC4R (0.42) | MC5RMC3RMC4RHDAC1HDAC6 | |
| SCHEMBL10085138 | 0.74 | HDAC3 (0.30) | HDAC1HDAC6 | |
| SCHEMBL16359032 | 0.73 | TLR7 (0.41) | MC5RMC3RMC4RMC1RNPSR1 | |
| SCHEMBL12387498 | 0.71 | VIM (0.44) | MC5RMC3RMC4RMC1RACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | MC5R 3529/4885MC3R 3280/4885MC4R 3225/4885 |
| US-20120027677-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | MC5R 3529/4885MC3R 3280/4885MC4R 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.